The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer

Journal of Urology

Volumn 171, Issue 4, 2004, Pages 1529-1532

  Chiang, Chih Hung ^a   Chen, Kuang Kuo ^a,b   Chang, Luke S ^a,b   Hong, Chen Jee ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Genotype; Polymorphism, single nucleotide; Prostate; Prostatic neoplasms; Risk

Indexed keywords

ADENINE; GUANINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

EID: 1642269851     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000116538.15995.93     Document Type: Article

References (20)

1. WHO: World Health Report. Available at http://www.who.int/cancer/resources/incidences/en/. Accessed July 2003.
2. Gronberg, H.: Prostate cancer epidemiology. Lancet, 361: 859, 2003
3. Cancer Registry Annual Report of Male Cancer Incidence Rate. Taiwan: Department of Health, 1998
4. Balk, S. P., Ko, Y. J. and Bubley, G. J.: Biology of prostate-specific antigen. J Clin Oncol, 21: 383, 2003
5. Xue, W., Irvine, R. A., Yu, M. C., Ross, R. K., Coetzee, G. A. and Ingles, S. A.: Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res, 60: 839, 2000
6. Gsur, A., Preyer, M., Haidinger, G., Zidek, T., Madersbacher, S., Schatzl, G. et al: Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis, 23: 1647, 2002
7. Jani, A. B. and Hellman, S.: Early prostate cancer: clinical decision-making. Lancet, 361: 1045, 2003
8. Xue, W. M., Coetzee, G. A., Ross, R. K., Irvine, R., Kolonel, L., Henderson, B. E. et al: Genetic determinants of serum prostate-specific antigen levels in healthy men from a multi-ethnic cohort. Cancer Epidemiol Biomarkers Prev, 10: 575, 2001
9. Partin, A. W., Epstein, J. I., Cho, K. R., Gittelsohn, A. M. and Walsh, P. C.: Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol, 141: 341, 1989
10. Meyers, F. J., Gumerlock, P. H., Chi, S. G., Borchers, H., Deitch, A. D. and deVere White, R. W.: Very frequency p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer, 83: 2534, 1998
11. Gurova, K. V., Roklin, O. W., Krivokrysenko, V. I., Chumakov, P. M., Cohen, M. B., Feinstein, E. et al: Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene, 21: 153, 2002
12. Shenk, J. L., Fisher, C. J., Chen, S. Y., Zhou, X. F., Tillman, K. and Shemshedini, L.: p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting bAR amino- to carboxyl-terminal interaction. J Biol Chem, 276: 38472, 2001
13. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P. et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 279: 563, 1998
14. Mantzoros, C. S., Tzonou, A., Signorello, L. B., Stampfer, M., Trichopoulos, D. and Adami, H. O.: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer, 76: 1115, 1997
15. Medeiros, R., Morais, A., Vasconcelos, A., Costa, S., Pinto, D., Oliveira, J. et al: Linkage between polymorphisms in the prostate specific antigen AREI gene region, prostate cancer risk, and circulating tumors cells. Prostate, 53: 88, 2002
16. Mai, K. T., Isotalo, P. A., Green, J., Perkins, D. G., Morash, C. and Collins, J. P.: Incidental prostatic adenocarcinomas and putative premalignant lesions in TURP specimens collected before and after the introduction of prostate-specific antigen screening. Arch Pathol Lab Med, 124: 1454, 2000
17. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E. et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445, 1997
18. Frankel, S., Smith, G. D., Donovan, J. and Neal, D.: Screening for prostate cancer. Lancet, 361: 1122, 2003
19. Bostwick, D. G., Graham, S. D., Jr., Napalkov, P., Abrahamsson, P. A., di Sant'agnese, P. A., Algaba, F. et al: Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology, 41: 403, 1993
20. Stamey, T. A., McNeal, J. E., Yemoto, C. M., Sigal, B. M. and Johnstone, I. M.: Biological determinants of cancer progression in men with prostate cancer. JAMA, 281: 1395, 1999